Watson Pharma (WPI) Receives FDA Approval for ANDA for Next Choice ONE DOSE

Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that its subsidiary Watson Laboratories, Inc., has received approval from the United States FDA for its Abbreviated New Drug Application (ANDA) for Next Choice™ ONE DOSE (Levonorgestrel Tablet, 1.5 mg), the generic equivalent to Teva Women's Health's Plan B One-Step®. Watson plans to launch the product immediately.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• FDA authorizes 11 ZYN Ultra nicotine pouches for Philip Morris
• Hinge Health signs $86M office lease in San Francisco
• Kimbell Royalty closes $221.2M mineral rights acquisition